Skip to main
IKT
IKT logo

Inhibikase Therapeutics (IKT) Market Capitalization Overview

Market Cap: $138.28M as of Jun 13, 2025

$138.28M
Past Month-$12.64M (8.37%)
As of Jun 13, 2025, Inhibikase Therapeutics (IKT) has a market capitalization of $138.28M. Over the past 30 days, its market cap has decreased by -8.48%, while in the last 12 months, it has decreased by -36.68%.

Market capitalization represents the total value of Inhibikase Therapeutics as perceived by the stock market. It is calculated by multiplying the current stock price by the total number of outstanding shares.

Inhibikase Therapeutics (IKT) Market Cap Formula = Stock Price * Shares Outstanding

The market cap of Inhibikase Therapeutics (IKT) helps investors assess the company's size and compare it with competitors for better investment decisions.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

Inhibikase Therapeutics (IKT) Market Cap History

DateMarket CapChange
Jun 2, 2025$152.41M-8.48%
May 1, 2025$166.53M+14.87%
Apr 1, 2025$144.97M-7.93%
Mar 3, 2025$157.46M+5.09%
Feb 3, 2025$149.83M-32.23%
Jan 2, 2025$221.07M+19.20%

Inhibikase Therapeutics (IKT) End of Year Market Cap History

DateMarket CapChange
2025$138.28M-36.68%
2024$218.38M+2,684.95%
2023$7.85M-37.83%
2022$12.62M-65.89%
2021$36.98M-46.68%
2020$69.36M

FAQs About Inhibikase Therapeutics (IKT) Market Cap

As of Jun 13, 2025, the market capitalization of Inhibikase Therapeutics (IKT) is $138.28M. Market cap represents the total value of a company’s outstanding shares and is a key indicator of its size in the stock market.

In the last 30 days, Inhibikase Therapeutics’s market capitalization has decreased by -8.37%, changing from $150.92M to $138.28M as of Jun 13, 2025.

In the last 3 months, Inhibikase Therapeutics’s market capitalization has increased by —, changing from – to – as of –.

In the year 2024, Inhibikase Therapeutics’s market capitalization increased from $7.85M in January to $218.38M in December, reflecting a 2,684.95% change.

In the past five years, Inhibikase Therapeutics (IKT) has had a compound annual growth rate (CAGR) of 25.79% in market capitalization. This means its market cap has grown at an average rate of 25.79% per year.

Inhibikase Therapeutics (IKT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.